Clinical Trial Comparing the Self-test for Cervicovaginal Sample Versus Samples From Service Provider (Xyto-Ro)

HPV DNA Clinical Trial

— Xyto-Ro  

Official title:

Non-inferiority Clinical Trial Comparing the Self-test for Cervicovaginal Sample Versus Sample Collection by the Service Provider for the Identification of HPV-RA DNA and Triage With p16 & ki67 Dual Staining.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04520464
• Other study ID #: DI/16/111/03/001
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 2020
• Est. completion date: October 2021

Study information

• Verified date: August 2020
• Source: Hospital General de México Dr. Eduardo Liceaga
• Contact: Carlos E Aranda Flores, Oncology
• Phone: (52) 55 2789 2000
• Email: aranda_floresc[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Problem Description When cervical cancer screening is needed, the Pap test (or Pap smears) is still the most common, although there are challenges that continue to prevent effective screening services in many countries, poor quality testing, long delays until screening is available, they give the results to women, poor population coverage and insufficient follow-up treatment. HPV testing can remove barriers related to access to screening services, since the woman can obtain the sample herself. Women's self-sampling for HPV testing has been used in a programmatic context in some countries. For a good impact, screening coverage must reach at least 70% of the target population. In the Region of the Americas, only seven countries have reported this level of coverage, so there is a great need for improvement.

Several factors make it difficult to improve coverage: most screening programs are unorganized, available mainly in urban areas, and based on the Pap test, which has been shown to have low sensitivity, limited and requires multiple consultations.

However, screening alone is not enough to prevent cervical cancer. Follow-up treatment of women with abnormal screening test results is necessary and remains a challenge.

Main objective To evaluate the effectiveness of cervicovaginal self-test in comparison with direct sampling by the service provider, for the identification of HR-HPV DNA via real-time PCTR and triage with dual staining biomarker p16 & ki67.

Methodology Under inclusion and exclusion criteria and signed informed consent, cervical sample will be taken with the corresponding method according to the randomization (self-test or service provider) and certify that the device did not cause damage or lacerations in the vaginal canal. In addition, an acceptability survey will be completed. All women with positive p16 & ki67 will be referred for colposcopy and biopsy. Patients will be informed her results with a specialist physician for guidance and indications.

Clinical study design is crossover, monocentric, randomized, open, and non-inferiority.

Statistical differences between self-test and service rpovider will be assesed.

Description:

STUDY POPULATION The target population is patients admitted to HGM Oncology Service for cervical cancer screening through self-sampling and sampling by a service provider. Sample size is 444 valid patients

PROCESS Visit 1 is an inclusion visit. Participant will be included in the research protocol in accordance with the inclusion and exclusion criteria established by the protocol, and the signed informed consent will be collected. Patient will be randomized and sample will also be taken with the corresponding method and the patient will be completed to certify that the device did not cause damage or lacerations in the vaginal canal.

Visit 2 will be on the third day after taking the first sample. In this visit, the sample will be taken with the corresponding method according to the randomization and the patient will be completed to certify that the device did not cause damage or lacerations in the vaginal canal. In addition, the acceptability survey will be completed.

Visit 3 will take place 21 calendar days after the second visit, the results will be delivered to the patient, all women with positive results of CINtec Plus (p16 & ki67) will be referred for colposcopy and biopsy; said biopsies will be submitted for the analysis of over-expression of p16 protein. At this last visit, the patient will be informed of the importance and need to discuss her results with a specialist doctor for guidance and indications.

STATISTIC ANALYSIS The information to be analyzed are the results and the final diagnosis obtained by the self-test method (XytoTest device) and the service provider of the Oncology Service of the Hospital General de México "Eduardo Liceaga".

To determine the non-inferiority of both samples, the Kappa index will be used and to determine the significance through the Wilcoxon T.

ETHICAL AND BIOSAFETY ASPECTS The study complies with the ethical considerations corresponding to the 1964 Helsinki World Assembly and with their respective modifications in the World Medical Assembly, Hong Kong, September 1989 and Edinburgh, Scotland, October 2000 and the Clarification note of Paragraph 29, added by the General Assembly of the WMA, Washington 2002.

The informed consent format is authorized by the ethics and research committee and strictly adhere to the general health law and its regulations on research and the guidelines of the international conference on Harmonization (ICH) on good clinical practice ( GCP).

The subject is considered enrolled in the study when they have signed the informed consent form, no form must be completed or any research or study procedure must be completed before obtaining the written informed consent.

Any decision that might influence the subject's decision to remain in the study should be made known to investigator immediately.

Confidentiality of the subject will be maintained, all persons involved in the research who have access to the information, are obliged to refrain from disclosing the subject's information or any personal information.

This study is subject to be audited by Mexican regulatory authorities, with or without prior notice to the research site.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 444
• Est. completion date: October 2021
• Est. primary completion date: July 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 25 Years to 64 Years

Eligibility

Inclusion Criteria:

• Signature of informed consent

• Women with an active sex life

• Women 25 to 64 years old

• Patients without hysterectomy, conization of the cervix.

• Patients without radiotherapy treatment, cervical chemotherapy.

• 24 hours before taking the sample, they should not use douches, ovules, lubricants or gels.

Exclusion Criteria:

• Patients who have not started a sexual life

• Patients with uterine surgery.

• Patients pregnant.

• Patients with vaginal bleeding.

• Patients who have had sexual activity 24 hours prior to taking the sample.

Related Conditions & MeSH terms

• HPV DNA
• Human Papillomavirus (HPV)-Related Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Diagnostic Test:
• Cervical samples for identification of HR-HPV DNA via real-time PCTR.
Identification of HR-HPV DNA via real-time PCTR.

Locations

Country	Name	City	State
Mexico	Hospital General de México Eduardo Liceaga	Ciudad de mexico

Sponsors (1)

Lead Sponsor	Collaborator
Hospital General de México Dr. Eduardo Liceaga

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess effectiveness of cervicovaginal diagnosis by self-test in comparison with direct sampling by the service provider.	Identification of HPV-HR DNA via real-time PCTR and triage with dual-staining biomarker p16 & ki67.	5 months
Secondary	Acceptability for self-test	A survey will be applied to assess self-test acceptability in comparison to direct sampling by service provider	5 months